Other hetero-combinations of antibodies targeting the ICMs PD-1 and 4-1BBL (also known as tumor necrosis factor receptor superfamily member 9 or CD137), PD-1 and lymphocyte-activating gene 3 (LAG3) [35], or CD137 and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) [36], among others, have been proposed to modulate the immune response in cancers. This evidence concerns the gene PDCD1 and cancer.